BLAINJECTION
Approved
Dec 2025
Lifecycle
Launch
Competitive Pressure
30/100
Data completeness
2/8 — Basic
NUFYMCO (ranibizumab-leyk) by Formycon is vegf-a, including the biologically active, cleaved form of this molecule, vegf110. First approved in 2025.
Drug data last refreshed 20h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NUFYMCO (ranibizumab-leyk) is a monoclonal antibody biosimilar targeting VEGF-A, approved in December 2025 as a follow-on biologic for neovascular eye diseases. It binds VEGF-A and its cleaved form VEGF110, preventing interaction with endothelial cell receptors to reduce pathologic neovascularization and vascular leakage in conditions including neovascular AMD, macular CNV, diabetic retinopathy, DME, and macular edema following retinal vein occlusion. The mechanism works by blocking endothelial cell proliferation and abnormal blood vessel formation.
Launch
Recent launch by Formycon entering a competitive (30% pressure score) established anti-VEGF market; expect scaled commercial infrastructure for field teams and market access specialists.
Mechanism of Action
VEGF-A, including the biologically active, cleaved form of this molecule, VEGF110. VEGF-A has been shown to cause neovascularization and leakage in models of ocular angiogenesis and vascular occlusion and is thought to contribute to pathophysiology of neovascular AMD, mCNV, DR, DME and macular…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
NUFYMCO positions you in a high-stakes biosimilar launch within ophthalmology, a specialty with concentrated prescriber bases and payer leverage. Roles will emphasize competitive pricing justification, formulary placement, and reimbursement strategy against entrenched reference products.
Brand Manager
Worked on NUFYMCO at Formycon? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.